File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in sexually active women aged 16-26 years

TitleThe impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in sexually active women aged 16-26 years
Authors
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
Citation
Journal Of Infectious Diseases, 2009, v. 199 n. 7, p. 936-944 How to Cite?
AbstractBackground. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with-20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received-1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7%(95%confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6,-11,-16, and-18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings. Trial registration. ClinicalTrials.gov identifiers: NCT00092521, NCT00092534, and NCT00092482. © 2009 by the Infectious Diseases Society of America.
Persistent Identifierhttp://hdl.handle.net/10722/60354
ISSN
2015 Impact Factor: 6.344
2015 SCImago Journal Rankings: 4.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWheeler, CMen_HK
dc.contributor.authorKjaer, SKen_HK
dc.contributor.authorSigurdsson, Ken_HK
dc.contributor.authorIversen, OEen_HK
dc.contributor.authorMauricio, HAen_HK
dc.contributor.authorPerez, Gen_HK
dc.contributor.authorBrown, DRen_HK
dc.contributor.authorKoutsky, LAen_HK
dc.contributor.authorTay, EHen_HK
dc.contributor.authorGarcía, Pen_HK
dc.contributor.authorAult, KAen_HK
dc.contributor.authorGarland, SMen_HK
dc.contributor.authorLeodolter, Sen_HK
dc.contributor.authorOlsson, SEen_HK
dc.contributor.authorTang, GWKen_HK
dc.contributor.authorFerris, DGen_HK
dc.contributor.authorPaavonen, Jen_HK
dc.contributor.authorSteben, Men_HK
dc.contributor.authorBosch, FXen_HK
dc.contributor.authorDillner, Jen_HK
dc.contributor.authorJoura, EAen_HK
dc.contributor.authorKurman, RJen_HK
dc.contributor.authorMajewski, Sen_HK
dc.contributor.authorMuñoz, Nen_HK
dc.contributor.authorMyers, ERen_HK
dc.contributor.authorVilla, LLen_HK
dc.contributor.authorTaddeo, FJen_HK
dc.contributor.authorRoberts, Cen_HK
dc.contributor.authorTadesse, Aen_HK
dc.contributor.authorBryan, Jen_HK
dc.contributor.authorLupinacci, LCen_HK
dc.contributor.authorGiacoletti, KEDen_HK
dc.contributor.authorJames, Men_HK
dc.contributor.authorVuocolo, Sen_HK
dc.contributor.authorHesley, TMen_HK
dc.contributor.authorBarra, Een_HK
dc.date.accessioned2010-05-31T04:08:58Z-
dc.date.available2010-05-31T04:08:58Z-
dc.date.issued2009en_HK
dc.identifier.citationJournal Of Infectious Diseases, 2009, v. 199 n. 7, p. 936-944en_HK
dc.identifier.issn0022-1899en_HK
dc.identifier.urihttp://hdl.handle.net/10722/60354-
dc.description.abstractBackground. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with-20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received-1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7%(95%confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6,-11,-16, and-18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings. Trial registration. ClinicalTrials.gov identifiers: NCT00092521, NCT00092534, and NCT00092482. © 2009 by the Infectious Diseases Society of America.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.orgen_HK
dc.relation.ispartofJournal of Infectious Diseasesen_HK
dc.titleThe impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in sexually active women aged 16-26 yearsen_HK
dc.typeArticleen_HK
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_HK
dc.identifier.authorityTang, GWK=rp00328en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1086/597309en_HK
dc.identifier.scopuseid_2-s2.0-65549116473en_HK
dc.identifier.hkuros155036en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-65549116473&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume199en_HK
dc.identifier.issue7en_HK
dc.identifier.spage936en_HK
dc.identifier.epage944en_HK
dc.identifier.isiWOS:000264056600004-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWheeler, CM=7202505711en_HK
dc.identifier.scopusauthoridKjaer, SK=7004418213en_HK
dc.identifier.scopusauthoridSigurdsson, K=35475355400en_HK
dc.identifier.scopusauthoridIversen, OE=7102966661en_HK
dc.identifier.scopusauthoridMauricio, HA=36710324400en_HK
dc.identifier.scopusauthoridPerez, G=16307983600en_HK
dc.identifier.scopusauthoridBrown, DR=7407095050en_HK
dc.identifier.scopusauthoridKoutsky, LA=7006120337en_HK
dc.identifier.scopusauthoridTay, EH=7004902850en_HK
dc.identifier.scopusauthoridGarcía, P=7201693727en_HK
dc.identifier.scopusauthoridAult, KA=7005241226en_HK
dc.identifier.scopusauthoridGarland, SM=7102220459en_HK
dc.identifier.scopusauthoridLeodolter, S=7005056838en_HK
dc.identifier.scopusauthoridOlsson, SE=7202623557en_HK
dc.identifier.scopusauthoridTang, GWK=7401633864en_HK
dc.identifier.scopusauthoridFerris, DG=17634377600en_HK
dc.identifier.scopusauthoridPaavonen, J=7102724434en_HK
dc.identifier.scopusauthoridSteben, M=6602790643en_HK
dc.identifier.scopusauthoridBosch, FX=7201833375en_HK
dc.identifier.scopusauthoridDillner, J=7007135194en_HK
dc.identifier.scopusauthoridJoura, EA=7004817276en_HK
dc.identifier.scopusauthoridKurman, RJ=7101640655en_HK
dc.identifier.scopusauthoridMajewski, S=7103224726en_HK
dc.identifier.scopusauthoridMuñoz, N=7102360543en_HK
dc.identifier.scopusauthoridMyers, ER=35433205900en_HK
dc.identifier.scopusauthoridVilla, LL=7102824355en_HK
dc.identifier.scopusauthoridTaddeo, FJ=6603004214en_HK
dc.identifier.scopusauthoridRoberts, C=35474924800en_HK
dc.identifier.scopusauthoridTadesse, A=6602812727en_HK
dc.identifier.scopusauthoridBryan, J=7202481712en_HK
dc.identifier.scopusauthoridLupinacci, LC=16307166200en_HK
dc.identifier.scopusauthoridGiacoletti, KED=15131768700en_HK
dc.identifier.scopusauthoridJames, M=10438802400en_HK
dc.identifier.scopusauthoridVuocolo, S=16403558200en_HK
dc.identifier.scopusauthoridHesley, TM=6603486789en_HK
dc.identifier.scopusauthoridBarra, E=36709232100en_HK
dc.identifier.citeulike4089361-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats